March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee’s approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

New recommendations on glycemic management for people with cancer, continuous glucose monitoring and the use of ...

Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming ...

A Swedish study reviewed 196 studies to understand biophobia, why people fear or dislike nature, and how those feelings can ...

Cancer related cognitive impairment in patients can stem from the cancer itself as well as the therapies used to treat it.

Children's Minnesota and Washburn Center for Children are tackling one of the most distressing trends in children's health care: the growing number of kids coming to hospital emergency departments in ...

Many rural older adults are struggling to access even the most basic health and social supports they need to stay healthy, ...

From my colleague Elaine Chen: Wave Life Sciences said today that interim data show its investigational siRNA therapy cut ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML ...